NCT05220995 is a clinical trial of protocol in Preimplantation Genetic Screening, sponsored by Gokalp Oner.

Who is sponsoring NCT05220995?

NCT05220995 is sponsored by Gokalp Oner.

What drugs are being tested in NCT05220995?

Interventions in NCT05220995: protocol.

What condition does NCT05220995 study?

NCT05220995 studies Preimplantation Genetic Screening.

Is NCT05220995 still recruiting?

NCT05220995 is currently status unknown. Last updated 2 February 2022.

Last reviewed 2022-02-02 · How we verify

NCT05220995

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effects of Miminal Stimulation Protocol on Preimplantation Genetic Screening

Status unknown Last updated 2 February 2022

What this trial tests

trial testing protocol in Preimplantation Genetic Screening in 200 participants. Status unknown.

Timeline

15 May 2021

Primary endpoint
23 January 2022

25 January 2022

Quick facts

Lead sponsor	Gokalp Oner
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	15 May 2021
Primary completion	23 January 2022
Estimated completion	25 January 2022
Sites	2 locations across Turkey (Türkiye)

Drugs / interventions tested

protocol

Conditions studied

Preimplantation Genetic Screening — all drugs for Preimplantation Genetic Screening →

Sponsor

Gokalp Oner

Who can join

Adults 38 to 45, female only, with Preimplantation Genetic Screening. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PGS has been the most effective method for embryo selection in IVF cycles. Euploidy rates decrease significantly with advancing maternal age (AMA). The dosage of gonadotropins also may be increased to recruit an adequate number of follicles in AMA women, minimal Stimulation Protocol (MSP) with the new combination of human menopausal gonadotrophin (hMG) and clomiphene citrate (CC) for controlled ovarian hyperstimulation is defined for poor ovarian response women. The aim of this study is to show minimal stimulation protocol affect euploidy and pregnancy rates in preimplatation genetic screening (PGS) cycles with single embryo transfer.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Effects of Minimal Stimulation Protocol on Preimplantation Genetic Screening.
Oner G, Karaman E, Elmali F, Altmisyedioglu S, et al · · 2025 · PMID 40566030 · DOI 10.3390/jcm14124285

Verify or expand the search:

Other trials of protocol

Trials testing the same drug.

NCT05457712 — Nutrition In Preoperative Pediatric Congenital Heart Disease · NA · unknown
NCT03814239 — Blood and Fluid Management During Scoliosis Surgery · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05220995 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gokalp Oner
Last refreshed: 2 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05220995.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing